Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    CBRNE

    Chemical Threat Medical Countermeasure Development

    By Global Biodefense StaffFebruary 27, 2017
    BAA Broad Agency Announcements
    Share
    Facebook LinkedIn Reddit Email

    The Biomedical Advanced Research and Development Authority (BARDA) has updated a funding mechanism for advanced development of chemical threat medical countermeasures.

    This effort is part of a multi-year, multi-topic Broad Agency Announcement (BAA) for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures for BARDA.

    Proposals are sought for medical countermeasures that treat the acute health effects of chemical threats, are easy to administer in a mass-casualty situation, and are rapidly effective as post-exposure therapies.

    Candidates should have demonstrated in vivo activity and potential for efficacy; and have held a pre-IND meeting with the FDA for licensure as an MCM prior to the submission of a white paper to the BARDA BAA.

    Specific areas of interest include:

    • Pulmonary Agents to prevent and treat lung damage resulting from exposure to agents such as
    • chlorine and phosgene.
    • Vesicants that limit harmful aspects of exposure to vesicating agents such as sulfur mustard and Lewisite.
    • Blood/Metabolic Agents to treat acute poisoning from agents such as cyanides. Antidotes should be easily administered by first responders in personal protective equipment.
    • Nerve Agents and OP Pesticides: Development of MCMs to treat seizures that are refractory to treatment with benzodiazepines.
    • Novel MCM Delivery Mechanisms

    BARDA notes that preference will be given to drug candidates that are already approved or are in clinical development for a conventional indication similar to that arising from exposure to a chemical agent.

    Further details are available via Solicitation Number: BAA-16-100-SOL-00001.

    ASPR BAA BARDA Chemical Weapons HHS
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense Headlines – February 26, 2017
    Next Article Viral Outbreak Tracking Software ‘Nextstrain’ Wins Open Science Prize

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.